FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
Season 5, Episode 47,
Oct 04, 2021, 07:07 PM
See more options
Embed Code
Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.
